ライフサイエンスコーパス: genital herpes

1 e for a role for IFI16 in protection against genital herpes.

2 quisition among patients with newly acquired genital herpes.

3 kin-lesion biopsy samples from subjects with genital herpes.

4 by showing that CVL samples prevented murine genital herpes.

5 inoculation was examined in a mouse model of genital herpes.

6 also become commonly associated with primary genital herpes.

7 d monthly for clinical signs and symptoms of genital herpes.

8 the reduction in transmission of symptomatic genital herpes.

9 ritical in developing effective vaccines for genital herpes.

10 rce (USPSTF) recommendation on screening for genital herpes.

11 counseling the patient with newly diagnosed genital herpes.

12 ans is vital for improving the management of genital herpes.

13 tic vaccine would help control the spread of genital herpes.

14 ns (84.7%) had never received a diagnosis of genital herpes.

15 ose regular sexual partners had a history of genital herpes.

16 ts and providers about care of patients with genital herpes.

17 was evaluated using the guinea pig model of genital herpes.

18 viral therapies for the control of recurrent genital herpes.

19 nto a candidate vaccine strain for HSV-2 and genital herpes.

20 even in subjects with no reported history of genital herpes.

21 ccinated persons who did and did not develop genital herpes.

22 well tolerated for suppression of recurrent genital herpes.

23 equire suppressive therapy for management of genital herpes.

24 ted in animal models of recurrent ocular and genital herpes.

25 bility is central to preventing and treating genital herpes.

26 on, and their reactivation leads to oral and genital herpes.

27 n adjuvant failed to show protection against genital herpes.

28 coprotein D (gD2) subunit vaccine to prevent genital herpes.

29 nner in otherwise healthy men and women with genital herpes.

30 ng potentiates the susceptibility of mice to genital herpes.

31 ht new strategies for vaccine design against genital herpes.

32 n the progesterone-induced B6 mouse model of genital herpes.

33 , including HSV type 2 (HSV-2), which causes genital herpes.

34 atic" vaccine against ocular, orofacial, and genital herpes.

35 tions for treatment of episodes of recurrent genital herpes.

36 of ASP2151 for episodic therapy of recurrent genital herpes.

37 ype 2 infection in mice and earlier onset of genital herpes.

38 s is an uncommon but serious complication of genital herpes.

39 between those patients with mild vs. severe genital herpes (1 in 3,800 vs. 1 in 6,600, P > .5).

40 930), trichomoniasis (1 study; n = 779), and genital herpes (1 study; n = 779).

41 ) 57 women at 70 clinic visits with clinical genital herpes; (2) 39 of the same women at 46 clinic vi

42 follow-up visit: trichomoniasis in 23 (18%); genital herpes, 20 (12%); gonorrhea, 9 (7%); syphilis, 7

43 roid, 29% had syphilitic ulcers, and 10% had genital herpes; 32% of the ulcer specimens were M-PCR ne

44 e 53 subjects who had no reported history of genital herpes, 33 (62 percent) subsequently reported ha

45 Chancroid (80%), syphilis (8%), and genital herpes (8%) were the most frequent diagnoses.

46 oniasis in 16 women (11%); syphilis, 9 (6%); genital herpes, 8 (6%); gonorrhea, 5 (4%); chlamydia, 5

47 ce partners were followed for recurrences of genital herpes; 89 were enrolled in a substudy of HSV-2

48 common as HSV-2 in causing first episodes of genital herpes, a disease that is associated with an inc

49 and B vaccine in the treatment of recurrent genital herpes, a randomized, placebo-controlled trial w

50 ls of protection against acute and recurrent genital herpes after vaginal challenge with wild-type vi

51 ficantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2-discordant coup

52 To examine the risks of genital herpes and antiherpes treatment during pregnancy

53 In a cohort of patients with genital herpes and healthy controls, the minor G allele

54 afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization cou

55 ex virus type 2 (HSV-2) is the cause of most genital herpes and is almost always sexually transmitted

56 Prevention of genital herpes and other sexually transmitted infections

57 be aware of the subclinical presentation of genital herpes and the potential these patients have for

58 rat may provide an excellent model to study genital herpes and to evaluate preventive strategies.

59 d 11 with HSV-2 antibodies but no history of genital herpes) and obtained daily swabs for viral cultu

60 e human pathogens that can cause cold sores, genital herpes, and blindness.

61 ects (72 percent) who reported no history of genital herpes, and HSV DNA was detected by the polymera

62 mitted infectious diseases, such as AIDS and genital herpes, and may have immunological effects.

63 HSV-2 but who reported having no history of genital herpes, and we compared their patterns of viral

64 The frequency of viral shedding in men with genital herpes appears comparable with that in women.

65 study, 52 patients with frequently recurrent genital herpes applied topical resiquimod gel 0.01% (twi

66 studies of the long-term clinical course of genital herpes are available.

67 cines against human papillomavirus (HPV) and genital herpes are in the final stages of testing.

68 monitored couples, most persons who transmit genital herpes are not aware of having the infection.

69 of subjects who did not have a recurrence of genital herpes at 6 months was 65% among valacyclovir re

70 ur HSV-2-seropositive women with symptomatic genital herpes attended a clinic daily during a 30-day p

71 c interaction between HIV-1 transmission and genital herpes being of special concern for control of b

72 Herpes simplex virus 1 and 2 cause genital herpes, blindness, encephalitis, and occasionall

73 microbicide and/or therapeutic agent against genital herpes by increasing resistance to HSV-2 and enh

74 Genital herpes can be caused by herpes simplex virus 2 (

75 cubation period and most persons who acquire genital herpes can identify the transmitting partner, a

76 Recently, the number of reported genital herpes cases caused by type 1 virus has increase

77 Not only does genital herpes cause painful, recurrent symptoms, it is

78 ence of HSV-1 decreased but the incidence of genital herpes caused by HSV-1 may be increasing.

79 Genital herpes, caused by herpes simplex virus, is the m

80 pDCs are critical in innate defense against genital herpes challenge, adaptive Th1 immunity develope

81 neurotropic infections such as cutaneous and genital herpes, chickenpox, and shingles.

82 ACIDFORM protected 21 (81%) of 26 mice from genital herpes, compared with 3 (12%) of 25 mice who rec

83 pants whose partners disclosed that they had genital herpes, compared with participants whose partner

84 ia, and a trend for less acute and recurrent genital herpes, compared with the gD2 vaccines.

85 anatomical locations may be responsible for genital herpes control in chronically infected individua

86 An effective vaccine for the prevention of genital herpes could help control this epidemic.

87 women were classified into 3 groups based on genital herpes diagnosis and treatment: genital herpes w

88 The primary end point was occurrence of genital herpes disease due to either HSV-1 or HSV-2 from

89 The primary end point was the occurrence of genital herpes disease in all subjects in Study 1 and in

90 lum and monophosphoryl lipid A (MPL) reduced genital herpes disease in HSV-1-seronegative women but n

91 A prophylactic vaccine for genital herpes disease remains an elusive goal.

92 ationships between these cells and recurrent genital herpes disease severity in the general populatio

93 iviral drugs in the treatment and control of genital herpes disease.

94 confidence interval [CI], -29 to 50) against genital herpes disease.

95 irus titers; 3) had decreased overt signs of genital herpes disease; and 4) did not succumb to lethal

96 pared with being unexposed, having untreated genital herpes during first or second trimester was asso

97 The acquisition of genital herpes during pregnancy has been associated with

98 Time since first genital herpes episode was significantly associated with

99 ns from 118 patients with culture-documented genital herpes episodes, and their results were compared

100 n may influence the epidemiology of clinical genital herpes, even if prior HSV-1 infection does not p

101 and 14 were given an incorrect diagnosis of genital herpes, for a ratio of true positive results to

102 ither the murine nor the guinea pig model of genital herpes fully recapitulates human disease.

103 The spectrum of genital herpes (GH) has been understudied in men, especi

104 An effective vaccine for genital herpes has been difficult to achieve because of

105 infections (STI), but diagnostic methods for genital herpes have not kept pace with the movement towa

106 Current therapies for genital herpes have only partial efficacy.

107 as vaginalis infection, primary or recurrent genital herpes, having bacterial vaginosis by Nugent cri

108 Of 11 HSV-2-seropositive men without a genital herpes history, 7 recognized typical recurrences

109 Fourteen of 15 mice were protected from genital herpes if they were challenged with HSV-2 pretre

110 rcentage reported having been diagnosed with genital herpes in 1999-2004 compared with 1988-1994 (1.8

111 1 genital herpes was less than that of HSV-2 genital herpes in cotton rats, and yet the model allowed

112 virus entry molecules have failed to prevent genital herpes in human trials.

113 ay be useful in the treatment and control of genital herpes in humans.

114 HSV-1 is an increasingly important cause of genital herpes in industrialized countries.

115 translated to significant protection against genital herpes in mice treated with 0.1% griffithsin gel

116 However, unlike partners with genital herpes in prospectively monitored couples, most

117 more, HSV-1 has become an important cause of genital herpes in some developed countries.

118 her efficacy against HSV-1 compared to HSV-2 genital herpes in the novel DMPA-synchronized cotton rat

119 rmine whether PRO 2000 could protect against genital herpes in vivo.

120 glycoprotein D vaccine has efficacy against genital herpes in women who are seronegative for both HS

121 ncreasing evidence that sexually transmitted genital herpes increases HIV acquisition, and the reacti

122 In addition, genital herpes increases the frequency of HIV infection

123 Genital herpes increases the risk of transmission and ac

124 to estimate the prevalence and incidence of genital herpes infection and to assess the relation betw

125 vealed increased risk of PTD associated with genital herpes infection if left untreated and a potenti

126 d effective for the suppression of recurrent genital herpes infection in HIV-infected individuals.

127 ulcers caused by HSV-2, which suggests that genital herpes infection likely increases the efficiency

128 rpes medications in mitigating the effect of genital herpes infection on the risk of PTD.

129 A vaccine that prevents genital herpes infection will have major public health b

130 poly I:C has been shown to protect mice from genital herpes infection, the mechanism by which these a

131 Using a mouse model of genital herpes infection, we demonstrate that both antib

132 who were seropositive reported a history of genital herpes infection.

133 (endocervix and ectocervix/vagina) to mimic genital herpes infections caused by herpes simplex virus

134 ntibody can provide passive immunity against genital herpes infections in mice; orally administered p

135 The proportion of HSV-1 among initial genital herpes infections was higher among men who had s

136 latform against primary and secondary female genital herpes infections.

137 simplex virus 1 (HSV-1), a leading cause of genital herpes, infects oral or genital mucosal epitheli

138 ing that the vaccine protected against HSV-1 genital herpes instead.

139 s to HSV-2 of 22% in the general population, genital herpes is 1 of the 3 most prevalent sexually tra

140 Genital herpes is a highly prevalent chronic disease cau

141 Importance: Genital herpes is a prevalent sexually transmitted infec

142 Genital herpes is an incurable, chronic disease that aff

143 sions and Relevance: Serologic screening for genital herpes is associated with a high rate of false-p

144 Most genital herpes is caused by HSV-2, although HSV-1 accoun

145 entral issue in the public health problem of genital herpes is the high proportion of genital HSV inf

146 Genital herpes is the main cause of genital ulcers world

147 In many developing countries genital herpes is untreated, and in the United States on

148 , the principal causative agent of recurrent genital herpes, is a highly prevalent viral infection wo

149 We studied the persistence of genital herpes lesion-derived HSV-specific CD8+ CTL from

150 Application of resiquimod to genital herpes lesions appeared to reduce the frequency

151 elivery, the standard of care for women with genital herpes lesions at the time of delivery, reduces

152 In genital herpes lesions, the superficial layers of strati

153 -2 gD2 antigen protected guinea pigs against genital herpes, limiting primary infection and reducing

154 interventions more specifically tailored to genital herpes may be useful and should be an important

155 DCs in the skin during primary or recurrent genital herpes may enhance HIV-1 infection of adjacent D

156 recognition by physicians that patients with genital herpes may have expert knowledge.

157 lines in HSV-2 infections, the prevalence of genital herpes may increase.

158 ositive for HSV-2 only reported a history of genital herpes more frequently (16.2%) than persons sero

159 valuated in primary culture systems and in a genital herpes murine model.

160 ies suggest that most sexual transmission of genital herpes occurs when persons shed virus but lack l

161 rica have measured the unfavorable effect of genital herpes on infected patients, health care resourc

162 The patient's genital herpes outbreaks were not controlled by high-dos

163 screening, harms of screening, reduction in genital herpes outbreaks.

164 hough HSV-2 remained the predominant type of genital herpes, over the 6-year span of this study, ther

165 The significant gap in knowledge on genital herpes pathogenesis has been further highlighted

166 in the prevalence of Incurable STDs (such as genital herpes); perhaps greater Importance of symptomat

167 ects with no prior history of oral/labial or genital herpes possessed HSV-specific T cell immunity bu

168 We evaluated a genital herpes prophylactic vaccine containing herpes si

169 The time to first genital herpes recurrence was significantly shorter in t

170 HIV+ patients who suffered more severe genital herpes recurrences had significantly lower HSV-s

171 ltured blood mononuclear cells and decreased genital herpes recurrences in an animal model.

172 The mouse model of genital herpes relies on medoxyprogesterone treatment of

173 g a partner who disclosed that he or she had genital herpes remained a strong protective factor again

174 onsible for herpes labialis (cold sores) and genital herpes, respectively.

175 nglia (DRG) to cause recurrent orofacial and genital herpes, respectively.

176 Efforts to prevent genital herpes should begin at an early age.

177 Genital herpes simplex is one of the most prevalent sexu

178 Visits to physicians for genital herpes simplex virus (HSV) infection continue to

179 Importance: Genital herpes simplex virus (HSV) infection is a preval

180 Primary genital herpes simplex virus (HSV) infection is commonly

181 Genital herpes simplex virus (HSV) reactivation is thoug

182 he efficacy of valacyclovir and acyclovir on genital herpes simplex virus (HSV) shedding was assessed

183 Attempts to develop a vaccine to prevent genital herpes simplex virus 2 (HSV-2) disease have been

184 Patients with newly acquired genital herpes simplex virus 2 (HSV-2) infection have vi

185 e epidemiological studies have reported that genital herpes simplex virus 2 (HSV-2) infection increas

186 study assessed 79 men (63 with a history of genital herpes simplex virus [HSV] type 2 infection, 5 w

187 Genital herpes simplex virus infections are widespread t

188 wice daily) for the suppression of recurrent genital herpes simplex virus infections in human immunod

189 Following genital herpes simplex virus type 2 (HSV-2) exposure, NK

190 icient (CXCL10(-/-)) mice which succumbed to genital herpes simplex virus type 2 (HSV-2) infection an

191 Genital herpes simplex virus type 2 (HSV-2) infection ca

192 min) relative to host immune defense against genital herpes simplex virus type 2 (HSV-2) infection ha

193 investigated the mechanism of resistance to genital herpes simplex virus type 2 (HSV-2) infection in

194 Clinical and virologic manifestations of genital herpes simplex virus type 2 (HSV-2) infection va

195 e vaccines are effective in animal models of genital herpes simplex virus type 2 (HSV-2) infection.

196 n = 188) from 29 patients with first-episode genital herpes simplex virus type 2 (HSV-2) infections w

197 Effective vaccines against genital herpes simplex virus type 2 (HSV-2) may need to

198 persons without past or current symptoms of genital herpes; studies evaluating accuracy and harms of

199 ter adjustment for sex, HSV type 1, oral and genital herpes symptoms, immigrant status, and the inter

200 ns with laboratory-documented newly acquired genital herpes, the median duration of the sexual relati

201 In spite of the high health burden of genital herpes, there is still no effective intervention

202 mptomatic but nevertheless fail to recognize genital herpes; they serve as reservoirs for transmissio

203 umber of persons have learned that they have genital herpes through serologic testing.

204 156 HSV-2-positive persons with a history of genital herpes to receive one of four doses of oral prit

205 gnancy events, including vaginal infections, genital herpes, urinary tract infections (UTIs), and oth

206 Thus, an effective genital herpes vaccine would be an important weapon in t

207 olunteers entering trials of investigational genital herpes vaccines, 6 of the 24 immunocompetent sub

208 inical diagnosis of syphilis, chancroid, and genital herpes was 93%, 53%, and 0% and specificity was

209 Serologic screening for genital herpes was associated with psychosocial harms, i

210 of valaciclovir for suppression of recurrent genital herpes was conducted among 1479 immunocompetent

211 The severity of HSV-1 genital herpes was less than that of HSV-2 genital herpe

212 for bacterial vaginosis, trichomoniasis, and genital herpes was performed in a high-prevalence popula

213 in the subjects with no reported history of genital herpes was similar to that in the subjects with

214 tage who reported having been diagnosed with genital herpes was statistically different (14.3% in 199

215 Using a mouse model of genital herpes, we found that HSV-1-infection-associated

216 Persons with genital herpes were randomized into 3 dose cohorts to re

217 clinical trial of a subunit vaccine against genital herpes were recently reported.

218 Signs and symptoms of genital herpes were recorded by the participants and cli

219 plex virus 2 (HSV-2) is the primary cause of genital herpes, which is one of the most common sexually

220 treatment: genital herpes without treatment, genital herpes with antiherpes treatment, and no herpes

221 d on genital herpes diagnosis and treatment: genital herpes without treatment, genital herpes with an

222 ikely plays a role in the epidemic spread of genital herpes worldwide.